1461088253-109104c0-765c-4eb4-899c-92daefa097a9

1. A method for determining if a subject of interest has pre-diabetes or diabetes, comprising
(a) comparing a proteomic profile of a test sample of saliva from a subject of interest with a proteomic profile of at least one control sample, wherein the proteomic profile of the test sample and the at least one control sample comprise information on the expression of at least one of cystatin C, alpha 2-macroglobulin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2, and wherein:
(i) if the at least one control sample is a non-diabetic reference value or a saliva sample from a non-diabetic subject, and the proteomic profile of the test sample does not show an elevated level of cystatin C, alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 RBP4) andor lipocalin 2 relative to the proteomic profile of the at least one control sample, the subject is determined not to have pre-diabetes or diabetes, and wherein if the proteomic profile of the test sample shows an elevated level of cystatin C, alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 relative to the proteomic profile of the at least one control-sample, the subject is determined to have prediabetes or diabetes;
(ii) if the at least one control sample is a diabetic reference value or a saliva sample from a subject with diabetes and the proteomic profile of the test sample does not show a decreased level of cystatin C, alpha 2-macroglobin (A2MG) transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 relative to the proteomic profile of the at least one control sample, then the subject is determined to have diabetes, and wherein if the proteomic profile of the test sample shows a decreased level of cystatin C, alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 relative to the proteomic profile of the at least one control sample, the subject is determined not to have diabetes; and
(iii) if the at least one control sample comprises a negative control comprising a non-diabetic reference value or a saliva sample from a non-diabetic subject and a positive control comprising a diabetic reference value or a saliva sample from a subject with diabetes, and the proteomic profile of the test sample shows a level of cystatin C, alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 that is intermediate between the proteomic profiles of the negative control and the positive control, then the subject is determined to have pre-diabetes.
2. The method of claim 1, wherein the proteomic profile of the test sample and at least one control sample further comprise information on the expression of at least one additional protein, wherein the at least one additional protein comprises alpha-1-antitrypsin, alpha 1 acid glycoprotein, uteroglobin, carbonic anhydrase 6 pyruvate kinase isozymes MIIM2, neutrophil collagenase, purine nucleoside phosphorylase, aldehyde dehydrogenase, fatty acid biding protein (epidermal), peroxiredoxin-1 -2, +-6 lamin AIC apolipoprotein B-100, annexin A2, carbonic anhydrase 1, carbonic anhydrase 2,
protein plunc, pancreatic ribonuclease, inter-a-trypsin inhibitor heavy chain HI, inter-a-trypsin heavy chain H4, nucleobindin-2, moesin, 14-3-3- epsilon, cystatin A, annexin A3, Protein S100-A7, phosphoglycerate kinase 1, annexin Al , isoform2 of P67936 tropomyosin a-4, kallikrein-10, desmoplakin, flavin reductase, grancalcin, andor calnexin, and wherein:
(i) if the at least one control sample is a non-diabetic reference value or a saliva sample from a non-diabetic subject, and the proteomic profile of the test sample does not show an elevated level of the at least one additional protein relative to the proteomic profile of the at least one control sample, the subject is determined not to have pre-diabetes or diabetes, and wherein if the proteomic profile of the test sample shows an elevated level of the at least one additional protein relative to the proteomic profile of the at least one control sample, the subject is determined to have prediabetes or diabetes;
(ii) if the reference sample is a diabetic reference value or a saliva sample from a diabetic subject, and the proteomic profile of the test sample does not show a decreased level of the at least one additional protein relative to the proteomic profile of the at least one control sample, the subject is determined to have prediabetes or diabetes, and wherein if the proteomic profile of the test sample shows a decreased level of the at least one additional protein relative to the proteomic profile of the at least one control sample, the subject is determined not to have pre-diabetes or diabetes; and
(iii) if the at least one control sample comprises a negative control comprising a non-diabetic reference value or a saliva sample from a non-diabetic subject, and a positive control comprising a diabetic reference value or a saliva sample from a subject with diabetes, and the proteomic profile of the test sample shows a level of the at least one additional protein that is intermediate between the proteomic profiles of the negative control and the positive control, then the subject is determined to have pre-diabetes.
3. The method of claim 1, wherein an increased level of cystatin C, alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 comprises at least a 1.2-fold increase relative to the proteomic profile of the at least one control sample; and wherein a decreased level of alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 comprises at least a 1.2-fold decrease relative to the proteomic profile of the at least one sample.
4. The method of claim 1, wherein the proteomic profile further comprises information on the expression of one or more of proteasome subunit, aldo-keto reductase family 1 member B 10, cathepsin Z, chitotriosidase isoform 2, 3, +4, transmembrane protease, serine 1 ID, transthyretin, glycogen phosphorylase, heterogeneous nuclear RNPs A21B 1, leukocyte elastase inhibitor, small proline-rich protein 2F, calmodulin-like protein 5, neuroblast differentiation AHNAK, histone cluster 1, Hle, kallikrein-13, chitinase-3-like protein 1, inter-alpha (Globulin) inhibitor H2, 14-3-3 protein eta, cofilin-1, retinol binding protein 4, plasma, basic proline-rich peptide IB-8a, isoform 2 of P60953 cdc 42 homolog, actin-related protein 213 complex subunit 5, ly61PLAUR domain-containing protein 3, actin-like protein 2, Rearranged VKA17V gene segment, brain acid soluble protein 1, golgi phosphoprotein 2, protein FAM49B (LI), and acidic leucine-rich nuclear phosphoprotein 32.
5. The method of claim 2, wherein the proteomic profile comprises information on the expression of five or more of protein plunc, pancreatic ribonuclease, inter-a-trypsin inhibitor heavy chain HI, inter-a-trypsin heavy chain H4, nucleobindin-2, moesin, 14-3-3-epsilon, cystatin A, annexin A3, Protein S100-A7, phosphoglycerate kinase 1, annexin Al, isotform2 of P67936 tropomyosin a-4, kallikrein-10, desmoplakin, flavin reductase, grancalcin, and calnexin.
6. The method of claim 2, wherein the proteomic profile comprises information on the expression of ten or more of protein plunc, pancreatic ribonuclease, inter-a-trypsin inhibitor heavy chain HI, inter-a-trypsin heavy chain 5 H4, nucleobindin-2, moesin, 14-3-3-epsilon, cystatin A, annexin A3, Protein S100-A7, phosphoglycerate kinase 1, annexin Al, isotform2 of P67936 tropomyosin a-4, kallikrein-10, desmoplakin, flavin reductase, grancalcin, and calnexin.
7. The method of claim 2, wherein the proteomic profile comprises information on the expression of fifteen or more of protein plunc, pancreatic ribonuclease, inter-a-trypsin inhibitor heavy chain HI, inter-a-trypsin heavy chain H4, nucleobindin-2, moesin, 14-3-3-epsilon, cystatin A, annexin A3, Protein S100-A7, phosphoglycerate kinase 1, annexin Al, isotform2 of P67936 tropomyosin a-4, kallikrein-10, desmoplakin, flavin reductase, grancalcin, and calnexin.
8. The method of claim 2, wherein the proteomic profile comprises all of protein plunc, pancreatic ribonuclease, inter-a-trypsin inhibitor heavy chain HI inter-a-trypsin heavy chain H4, nucleobindin-2, moesin, 14-3-3-epsilon, cystatin A, annexin A3, Protein S100-A7, phosphoglycerate kinase 1, annexin Al, isotform2 of P67936 tropomyosin a-4, kallikrein-10, desmoplakin, flavin reductase, grancalcin, and calnexin.
9. The method of claim 2, wherein the proteomic profile further comprises information on the expression of alpha-1-antitrypsin, alpha 2-macroglobulin, cystatin C, plasma retinol binding protein 4 (RBP4), and transthyretin.
10. The method of claim 1, wherein the diabetes is type 2 diabetes.
11. The method of claim 1, wherein the diabetes is type 1 diabetes.
12. The method of claim 1, further comprising determining a level of hemoglobin A1C for the subject, wherein an elevated level of hemoglobin A1C relative to a non-diabetic A1C control value confirms a diagnosis of pre-diabetes or diabetes.
13. The method of claim 1, wherein the subject is obese.
14. The method of claim 1, wherein the proteomic profile is determined using a lateral flow device.
15. A method for monitoring the efficacy of an anti-diabetes therapy in a subject comprising:
obtaining a first saliva sample from the subject at a first time point;
administering the anti-diabetes therapy to the subject;
obtaining a second saliva sample from the subject at a second time point;
determining a proteomic profile for each of the first and second saliva samples, wherein the proteomic profiles of the first and second saliva samples comprise information on the expression of at least one of cystatin C,alpha 2-macroglobulin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) and lipocalin 2, and wherein:
(i) if the proteomic profile of the second saliva sample shows a decrease in a level of cystatin C, alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 relative to the proteomic profile of the first saliva sample, the anti-diabetes therapy is determined to be effective; and
(ii) if the proteomic profile of the second saliva sample does not show a decrease in a level of cystatin C, alpha 2-macroglobin (A2MG), transthyretin (TTR), plasma retinol binding protein 4 (RBP4) andor lipocalin 2 relative to the proteomic profile of the first saliva sample, the anti-diabetes therapy is determined to be ineffective.
16. The method of claim 15, wherein the proteomic profiles of the first and second saliva samples further comprise information on the expression of at least one additional protein, wherein the at least one additional protein comprises alpha-1-antitrypsin, alpha 1 acid glycoprotein, uteroglobin, carbonic anhydrase 6, pyruvate kinase isozymes MIIM2, neutrophil collagenase, purine nucleoside phosphorylase, aldehyde dehydrogenase, fatty acid biding protein (epidermal), peroxiredoxin-1, -2, +-6, lamin AIC, apolipoprotein B-100, annexin A2, carbonic anhydrase 1, carbonic anhydrase 2,protein plunc, pancreatic ribonuclease, inter-a-trypsin inhibitor heavy chain HI, inter-a-trypsin heavy chain H4, nucleobindin-2, moesin, 14-3-3- epsilon, cystatin A, annexin A3, Protein S100-A7, phosphoglycerate kinase 1, annexin Al, isoform2 of P67936 tropomyosin a-4, kallikrein-10, desmoplakin, flavin reductase, grancalcin, andor calnexin, and wherein:
(i) if the proteomic profile of the second saliva sample shows a decrease in a level of the at least one additional protein relative to the proteomic profile of the first saliva sample, the anti-diabetes therapy is determined to be effective; and
(ii) if the proteomic profile of the second saliva sample does not show a decrease in a level of the at least one additional protein relative to the proteomic profile of the first saliva sample, the anti-diabetes therapy is determined to be ineffective.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An electrophoretic medium comprising a first electrically charged particle suspended in a suspending fluid, the first particle having a polymeric shell having repeating units derived from at least one monomer the homopolymer of which is incompatible with the suspending fluid, the electrophoretic medium further comprising a second electrically charged particle having at least one optical property differing from that of the first electrically charged particle, the second electrically charged particle having a polymeric shell.
2. An electrophoretic medium according to claim 1 wherein the polymeric shell of the first particle further comprises repeating units derived from at least one monomer the homopolymer of which is compatible with the suspending fluid.
3. An electrophoretic medium according to claim 2 wherein the at least one monomer forming the compatible homopolymer comprises from about 15 to about 99 per cent by weight of the polymer shell of the first particle.
4. An electrophoretic medium according to claim 3 wherein the at least one monomer forming the compatible homopolymer comprises from about 50 to about 99 per cent by weight of the polymer shell of the first particle.
5. An electrophoretic medium according to claim 2 wherein the monomer forming the compatible homopolymer comprises lauryl methacrylate and the monomer forming the incompatible homopolymer comprises any one or more or styrene, t-butyl methacrylate and N-vinylpyrrolidone.
6. An electrophoretic medium according to claim 1 wherein the suspending fluid comprises a hydrocarbon.
7. An electrophoretic medium according to claim 1 wherein the monomer forming the incompatible homopolymer comprises any one of more of acrylates and methacrylates formed from alcohols containing not more than about eight carbon atoms, said alcohols optionally containing hydroxyl or fluoro substituents; acrylamides and methacrylamides; N,N-dialkylacrylamides; N-vinylpyrrolidone; styrene and derivatives thereof vinyl esters; vinyl halides; polyfluoroaromatic molecules containing a polymerizable functional group; and silicone-containing molecules containing a polymerizable functional group.
8. An electrophoretic medium according to claim 7 wherein the monomer forming the incompatible homopolymer comprises any one of more of methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, t-butyl methacrylate, octyl methacrylate, 2-ethylhexyl methacrylate, 2-hydroxyethyl methacrylate, trifluoroethyl methacrylate, 2,2,3,4,4,4-hexafluorobutyl acrylate, 2,2,3,4,4,4-hexafluorobutyl methacrylate, acrylamide, acrylic acid, acrylonitrile, methyl vinyl ketone, methacrylamide, N-vinylpyrrolidone, styrene, vinyl acetate, vinyl chloride, vinylidene chloride, and pentafluorostyrene.
9. An electrophoretic medium according to claim 1 wherein the first particle comprises titania and the second particle comprises carbon black or copper chromite.
10. An electrophoretic medium comprising:
a suspending fluid;
a plurality of first electrically charged particles suspended in the suspending fluid, the first electrically charged particles having a polymeric shell; and
a plurality of second electrically charged particles suspended in the suspending fluid, the second electrically charged particles having an optical property differing from that of the first electrically charged particles, and a polymeric shell;
wherein the polymeric shells are arranged such that homoaggregation of the first and second particles is thermodynamically favored over heteroaggregation.
11. An electrophoretic medium according to claim 10 wherein the polymeric shells of the first and second particles each comprise repeating units derived from at least one monomer the homopolymer of which is incompatible with the suspending fluid.
12. An electrophoretic medium according to claim 11 wherein each polymeric shell further comprises repeating units derived from at least one monomer the homopolymer of which is compatible with the suspending fluid.
13. An electrophoretic medium according to claim 12 wherein the at least one monomer forming the compatible homopolymer comprises from about 15 to about 99 per cent by weight of the polymer shell.
14. An electrophoretic medium according to claim 13 wherein the at least one monomer forming the compatible homopolymer comprises from about 50 to about 99 per cent by weight of the polymer shell.
15. An electrophoretic medium according to claim 12 wherein the monomer forming the compatible homopolymer comprises lauryl methacrylate and the monomer forming the incompatible homopolymer comprises any one or more or styrene, t-butyl methacrylate and N-vinylpyrrolidone.
16. An electrophoretic medium according to claim 11 wherein the monomer forming the incompatible homopolymer comprises any one of more of acrylates and methacrylates formed from alcohols containing not more than about eight carbon atoms, said alcohols optionally containing hydroxyl or fluoro substituents; acrylamides and methacrylamides; N,N-dialkylacrylamides; N-vinylpyrrolidone; styrene and derivatives thereof vinyl esters; vinyl halides; polyfluoroaromatic molecules containing a polymerizable functional group; and silicone-containing molecules containing a polymerizable functional group.
17. An electrophoretic medium according to claim 16 wherein the monomer forming the incompatible homopolymer comprises any one of more of methyl methacrylate, ethyl methacrylate, butyl methacrylate, isobutyl methacrylate, t-butyl methacrylate, octyl methacrylate, 2-ethylhexyl methacrylate, 2-hydroxyethyl methacrylate, trifluoroethyl methacrylate, 2,2,3,4,4,4-hexafluorobutyl acrylate, 2,2,3,4,4,4-hexafluorobutyl methacrylate, acrylamide, acrylic acid, acrylonitrile, methyl vinyl ketone, methacrylamide, N-vinylpyrrolidone, styrene, vinyl acetate, vinyl chloride, vinylidene chloride, and pentafluorostyrene.
18. An electrophoretic medium according to claim 10 wherein the suspending fluid has a dielectric constant less than about 5.
19. An electrophoretic medium according to claim 10 wherein the suspending fluid comprises a hydrocarbon.
20. An electrophoretic medium according to claim 19 wherein the suspending fluid comprises an aliphatic hydrocarbon.
21. An electrophoretic medium according to claim 19 wherein the suspending fluid comprises an aryl-alkane or dodecylbenzene.
22. An electrophoretic medium according to claim 10 having an operating voltage threshold.
23. An electrophoretic medium according to claim 10 wherein the suspending fluid and the particles are retained within a plurality of capsules or cells.
24. An electrophoretic display comprising an electrophoretic medium according to claim 10 and at least one electrode disposed adjacent the electrophoretic medium and arranged to apply an electric field thereto.
25. An electrophoretic medium according to claim 10 wherein the first electrically charged particles comprise titania and the second electrically charged particles comprise carbon black or copper chromite.